



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/552,177	
			Filing Date	October 5, 2005	
			First Named Inventor	Ahearn, Joseph M.	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	021182-000410US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
								<input type="checkbox"/>
								<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/GG/	A1	BUYON, JP, et al., "Assessment of disease activity and impending flare in patients with systemic lupus erythematosus," <u>Arthritis Rheum.</u> , 1992, Vol. 35, pp. 1028-1037.			
↓	A2	FALK, RJ., et al., "Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus," <u>N. Engl. J. Med.</u> , 1985, Vol. 312, pp. 1594-1599.			
	A3	MANZI, S., et al., "Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity," <u>Arthritis & Rheumatism</u> , July 1996, Vol. 39, No. 7, pp. 1178-1188.			
	A4	MANZI, S., et al., "New insights into complement: a mediator of injury and marker of disease activity in systemic lupus erythematosus," <u>Lupus</u> , 2004, Vol. 13, pp. 1-6.			
	A5	NAVRATIL, JS, et al., "Apoptosis and autoimmunity: complement deficiency and systemic lupus erythematosus revisited," <u>Curr. Rheumatol. Rep.</u> , 2000, Vol. 2, pp. 32-38.			
↓	A6	RICKER, DM., et al., "Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels," The Lupus Nephritis Collaborative Study Group, <u>Am. J. Kidney Dis.</u> , 1991, Vol. 18, pp. 678-685.			
/GG/	A7	SENALDI, G., et al., "Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus," <u>Ann. Rheum. Dis.</u> , 1988, Vol. 47, pp. 913-917.			

Examiner Signature	/Gailene Gabel/ (12/04/2008)	Date Considered	12/04/2008
--------------------	------------------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.